For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human Aβ(1-40) High Specificity Detection Kit is designed for detection and quantitation of human Aβ(1-40) in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Amyloid beta (Aβ) is a short peptide derived from a transmembrane protein, the amyloid precursor protein (APP), by proteolysis. The β- and γ-secretases cleave the respective N- and C-terminal ends of the Aβ sequence, liberating the Aβ peptide from APP. Aβ40 is the major species of Aβ produced by neurons and other cells, and accounts for over 70% of total Aβ produced, while the remainder is typically composed Aβ42 and other size variants ranging from 36 to 43 AA in length. Interestingly, it has been observed by some that the Aβ40/Aβ42 ratio increased in cerebrospinal fluid of AD patients. Aβ40 could be an important biomarker for detecting Alzheimer’s disease progression. This AlphaLISA kit has been designed to detect Aβ40 in cell culture supernatants and cerebrospinal fluid.
|Assay Target Class||Peptide|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Dry Ice|
|Therapeutic Area||Central Nervous System|
|Unit Size||10,000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.